Literature DB >> 22073605

[Analysis of predominant bacterial species and clinical backgrounds in lung abscess patients].

Osamu Nagashima1, Shinichi Sasaki, Yukiko Nanba, Yoko Katsura, Hidenori Takekawa, Sachiko Kuriyama, Yasuyo Aso, Yasuko Yoshioka, Takeshi Nakazawa, Sigeru Tominaga.   

Abstract

We reviewed the clinicopathological characteristics of lung abscesses retrospectively. We analyzed 89 patients hospitalized from July 1984 to May 2009. Most were men (76/89). There were large proportions with alcohol consumption (29.2%) and dental caries or gingivitis (60.7%). Furthermore, those without other diseases accounted for only 13.5%. Predominant infectious species were clear in 43 cases (48.3%) including identification of bacteria. The identification rate of predominant bacteria improved from 38.5% to 56.0% after initiation of the introduction of expectoration culture, bronchoscopic specimen collection and gingival culture in 2003, facilitating clarification of the predominant bacteria. The Streptococcus anginosus group with predominant bacteria being slightly aerobic streptococci, anaerobic bacterium, and aerobic bacterium was detected in 10, 12, and 31 cases, respectively. The improvement in the identification rate of predominant bacteria was achieved by carrying out examination with close liaison with the staff of our inspection room. In selecting antimicrobials based on diagnostic significance, we should focus on positive identification of predominant bacteria, a factor which appears to have major clinical significance.

Entities:  

Mesh:

Year:  2011        PMID: 22073605

Source DB:  PubMed          Journal:  Nihon Kokyuki Gakkai Zasshi        ISSN: 1343-3490


  1 in total

Review 1.  Lung abscess-etiology, diagnostic and treatment options.

Authors:  Ivan Kuhajda; Konstantinos Zarogoulidis; Katerina Tsirgogianni; Drosos Tsavlis; Ioannis Kioumis; Christoforos Kosmidis; Kosmas Tsakiridis; Andrew Mpakas; Paul Zarogoulidis; Athanasios Zissimopoulos; Dimitris Baloukas; Danijela Kuhajda
Journal:  Ann Transl Med       Date:  2015-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.